These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16756583)

  • 1. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?
    Barnes M; Lawford BR; Burton SC; Heslop KR; Noble EP; Hausdorf K; Young RM
    Aust N Z J Psychiatry; 2006; 40(6-7):575-80. PubMed ID: 16756583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia.
    George TP; Ziedonis DM; Feingold A; Pepper WT; Satterburg CA; Winkel J; Rounsaville BJ; Kosten TR
    Am J Psychiatry; 2000 Nov; 157(11):1835-42. PubMed ID: 11058482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
    Goff DC; Henderson DC; Amico E
    Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
    Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does smoking reduce akathisia? Testing a narrow version of the self-medication hypothesis.
    de Leon J; Diaz FJ; Aguilar MC; Jurado D; Gurpegui M
    Schizophr Res; 2006 Sep; 86(1-3):256-68. PubMed ID: 16814524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy.
    Buckley PF
    J Clin Psychiatry; 2008 May; 69(5):e14. PubMed ID: 18681759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do atypical antipsychotics really enhance smoking reduction more than typical ones?: the effects of antipsychotics on smoking reduction in patients with schizophrenia.
    Wu BJ; Chen HK; Lee SM
    J Clin Psychopharmacol; 2013 Jun; 33(3):319-28. PubMed ID: 23609378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use.
    Lévy E; Margolese HC; Annable L; Chouinard G
    Can J Psychiatry; 2004 Jun; 49(6):398-402. PubMed ID: 15283536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the effects of nicotine on schizophrenia and antipsychotic medications.
    Lyon ER
    Psychiatr Serv; 1999 Oct; 50(10):1346-50. PubMed ID: 10506305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset.
    Berna F; Misdrahi D; Boyer L; Aouizerate B; Brunel L; Capdevielle D; Chereau I; Danion JM; Dorey JM; Dubertret C; Dubreucq J; Faget C; Gabayet F; Lancon C; Mallet J; Rey R; Passerieux C; Schandrin A; Schurhoff F; Tronche AM; Urbach M; Vidailhet P; Llorca PM; Fond G;
    Schizophr Res; 2015 Dec; 169(1-3):255-261. PubMed ID: 26589388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication.
    Nedic Erjavec G; Uzun S; Nikolac Perkovic M; Kozumplik O; Svob Strac D; Mimica N; Hirasawa-Fujita M; Domino EF; Pivac N
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Jul; 77():228-235. PubMed ID: 28461252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.